KRAS and colorectal carcinoma: Although KRAS mutations showed no significant positive outcomes in 1564 CRC-II and CRC-III patients in a study by Roth et al., (stage corrected HR, 1.05; 95% CI, 0.85 to 1.28; p = 0.66) [28], its mutation was shown to be associated with poor prognosis in 511 tumours (HR, 0·81; 95% CI, 0·68 to 0·96; p = 0·014) in another study [29].